3 results
Not approvedWill not start
Primary:Long-term safety of nivolumab in participants on treatment and in follow upExploratory:To follow participants who have completed therapy and are in or have completed follow-up on a parent study investigating nivolumab or nivolumab…
Approved WMOCompleted
To evaluate the dose response relationship of LNP023 on the reduction in proteinuria versus placebo after 90 days of treatment in patients with IgA nephropathy.
Approved WMOCompleted
The purpose of this study is to ascertain the efficacy, safety, tolerability and pharmacokineticsof LNP023 over a 24-week treatment period compared with rituximab in subjects with MN.